#Immuno-Oncology Clinical Trials Market share

[health-views-updates]

Oncology Drugs Market 2024 Share, Trend and Segmentation Forecast 2032

SNS Insider’s latest report on the Oncology Drugs Market Revenue reveals a market poised for accelerated growth, driven by rising cancer rates, advancements in targeted therapies, and breakthroughs in immunotherapy. The market's trajectory is bolstered by a growing demand for personalized medicine, which continues to reshape oncology care. Key players in the industry are developing a diverse pipeline of drugs that aim to improve survival rates and quality of life for cancer patients worldwide.

As global cancer incidence rises, the demand for effective and accessible oncology drugs has grown substantially. Factors such as increased cancer awareness, aging populations, and higher investment in research and development are transforming the oncology drugs landscape. Pharmaceutical and biotechnology companies are focusing on a range of innovative treatment options, including precision medicine, which tailors drugs to individual genetic profiles, and immunotherapy, which strengthens the body’s immune response to cancer cells.

The report also emphasizes the role of digital transformation in the market, which is enhancing the development and delivery of oncology drugs. Through advanced data analytics, artificial intelligence, and digital platforms, companies are able to accelerate drug discovery, optimize clinical trials, and improve patient outcomes. These technological advancements are expected to further catalyze market expansion, making oncology drugs more accessible and effective for patients globally.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/3241

Key Market Drivers and Trends

Rising Prevalence of Cancer Cancer remains one of the leading causes of death globally, with millions of new cases reported each year. This alarming trend is creating an urgent need for novel oncology drugs that can offer improved survival outcomes. In addition, rising awareness about early detection and treatment options is boosting the demand for effective cancer therapies.

Advances in Immunotherapy and Targeted Treatments The growing understanding of cancer biology has led to the development of immunotherapy and targeted drugs that work on specific genes and proteins associated with cancer cells. These drugs offer a tailored approach, reducing side effects and improving efficacy. Recent breakthroughs in immuno-oncology have shown promising results, with some therapies even achieving remission in advanced-stage cancers.

Personalized Medicine and Genetic Profiling Personalized medicine, which involves tailoring treatments based on individual patient characteristics, is becoming a key approach in oncology. Genetic profiling allows healthcare providers to design treatment regimens that are more effective and minimize adverse effects, providing a higher quality of life for patients. This approach has gained significant traction and is anticipated to drive long-term growth in the oncology drugs market.

Market Segmentation and Regional Insights

The SNS Insider report offers detailed segmentation of the oncology drugs market based on drug class, therapy type, indication, and region. Among drug classes, monoclonal antibodies are gaining considerable traction due to their effectiveness in targeting specific cancer cells. On a regional basis, North America continues to lead the global market due to its well-established healthcare infrastructure, significant investment in R&D, and high adoption of advanced therapies. Meanwhile, Asia-Pacific is emerging as a rapidly growing market, driven by a large patient population, increased healthcare spending, and growing awareness of cancer treatments.

Challenges and Opportunities

While the oncology drugs market shows tremendous potential, it also faces challenges such as high treatment costs, complex regulatory requirements, and the need for extensive clinical trials. However, government initiatives aimed at improving cancer care, coupled with collaborations between pharmaceutical companies and research institutions, are helping to mitigate these barriers. Additionally, as healthcare providers and insurers recognize the value of innovative therapies, the market is expected to benefit from increased funding and improved patient access to advanced treatments.

Future Outlook

SNS Insider’s analysis projects sustained growth in the oncology drugs market over the coming years, with innovations in biotechnology and digital health expected to play a pivotal role. With new oncology drugs under development and continued investments in precision medicine, the industry is well-positioned to deliver therapies that will improve cancer treatment outcomes and patient experiences. Market players are likely to focus on enhancing drug efficacy, reducing costs, and making treatments more accessible worldwide, reinforcing the essential role of oncology drugs in combating the global cancer burden.

About Us SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us: Akash Anand – Head of Business Development & Strategy info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[marketreports-blog]

The global immuno-oncology clinical trials market size was valued at USD 8.30 billion in 2023 and is anticipated to reach around USD 35.37 billion by 2033, growing at a CAGR of 15.6% from 2024 to 2033. North America dominated the market and accounted for the largest revenue share of 54.0% in 2023.

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology

[rohans18]

Immuno-Oncology Clinical Trials Market Size, Reports, Demands, Share - Forecast 2029

Global Immuno-Oncology Clinical Trials Market, By Phase (Phase I, Phase I, Phase III, Phase IV), Design (Interventional Trials, Observational Trials, Expanded Access Trials), Indication (Solid Tumours, Hematological Cancer), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Immuno-Oncology Clinical Trials marketing report. The report has a lot to offer to both established and new players in the Immuno-Oncology Clinical Trials industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Immuno-Oncology Clinical Trials market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the Immuno-Oncology Clinical Trials market report are Merck Sharp & Dohme Corp., Northeast Pharmaceutical Group Co., Ltd., Cayman Chemical, Tokyo Chemical Industry Co. Ltd., ,Kaiyuan Hengtai Nutrition Co., Ltd., ChengDa PharmaCeuticals Co.,Ltd., Avanscure Lifesciences Pvt. Ltd., Biosint SpA, Maxsun Industries, MANUS AKTTEVA BIOPHARMA LLP, Huanggang Huayang Pharmaceutical Co., Ltd., Merck KGaA, Viachem Limited and Spectrum Chemical Manufacturing Corp., among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-clinical-trials-market

With the help of credible Immuno-Oncology Clinical Trials market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Immuno-Oncology Clinical Trials market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[cavixorg]

Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive. The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers.  And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors. It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California. Who Are The Major Owners Of AMAM Stock? 17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments. AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions. In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months. Short Sellers Of Ambrx Biopharma? November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares. Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.   Competitors Of AMAM The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX). All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy. Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms. Entera Bio And Ambrx Biopha

rma? Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market. Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating. With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one. Shares Of Ambrx Rise After Promoting Early Safety Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate. In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing. In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15. How Simple Is It For Ambrx Biopharma To Raise Money? Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity. Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year. Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock. What Are The Average Rating And Price Objective For Ambrx Biopharma? Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00. According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00. By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00. Is AMAM A Successful Business? The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of

$111.72 million. This is sufficient to fund its $70.16M yearly cash burn. AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%. According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money. The Basics Of Ambrx Biopharma The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector. AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence. The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history. Recommendations Most Recent From AMAM Analysts On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating. On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target. On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target. In 2022, Should I Buy Or Sell Ambrx Biopharma Stock? In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering. At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022. Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end. Ambrx Biopharma Stock Forecast 2022 While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market. The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975. The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28. Ambrx Biopharma Stock Forecast

2023 AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00. From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.

[stocklivemarket]

Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive. The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers.  And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors. It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California. Who Are The Major Owners Of AMAM Stock? 17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments. AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions. In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months. Short Sellers Of Ambrx Biopharma? November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares. Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.   Competitors Of AMAM The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX). All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy. Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms. Entera Bio And Ambrx Biopha

rma? Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market. Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating. With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one. Shares Of Ambrx Rise After Promoting Early Safety Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate. In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing. In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15. How Simple Is It For Ambrx Biopharma To Raise Money? Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity. Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year. Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock. What Are The Average Rating And Price Objective For Ambrx Biopharma? Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00. According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00. By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00. Is AMAM A Successful Business? The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of

$111.72 million. This is sufficient to fund its $70.16M yearly cash burn. AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%. According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money. The Basics Of Ambrx Biopharma The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector. AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence. The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history. Recommendations Most Recent From AMAM Analysts On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating. On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target. On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target. In 2022, Should I Buy Or Sell Ambrx Biopharma Stock? In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering. At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022. Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end. Ambrx Biopharma Stock Forecast 2022 While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market. The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975. The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28. Ambrx Biopharma Stock Forecast

2023 AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00. From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.

[erasamuel]

Immuno-oncology Drugs Market Will Hit Big Revenues In Future | Biggest Opportunity Of 2022

Latest edition released by AMA on Global Immuno-oncology Drugs Market to regulate the balance of demand and supply. This intelligence report on Immuno-oncology Drugs includes Investigation of past progress, ongoing market scenarios, and future prospects. Data True to market on the products, strategies and market share of leading companies of this particular market are mentioned. It’s a 360-degree overview of the global market’s competitive landscape. The report further predicts the size and valuation of the global market during the forecast period. Some of the key players profiled in the study are Amgen, Inc (United States), AstraZeneca, Plc (United Kingdom), Bristol-Myers Squibb (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Merck & Co.(United States), Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Novartis International AG (Switzerland), AbbVie, Inc. (United States), Pfizer Inc. (United States), Sanofi S.A. (France), EMD Serono, Inc. (United States), Gilead Sciences Inc. (United States), Prometheus Therapeutics & Diagnostics (United States), Aduro BioTech (United States), Galena Biopharma (United States)

According to the International Agency for Research on Cancer around 18.1 million new cancer cases and 9.6 million cancer deaths. Immuno-oncology refers to the use of the body's natural defenses to treat cancer and works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in the functionality of healthy cells. It helps the immune system to recognize and target cancer cells. Further, ongoing clinical trials for the development of innovative products for cancer treatment is driving the Global Immuno-Oncology market. Market Trends: Ongoing Clinical Trial for the Development of Innovative Products

Emergence of Targeted and Combination Therapies

 

Opportunities: Companies Offering Opportunities for Next Generation Immunotherapy

Market Drivers: Introduction of Novel Oncology Therapies with Lesser Side Effects

Improved Therapeutic Outcomes in Cancer Treatment

Rising Prevalence of Cancer and Usage of Number of Therapies

Growing Geriatric Population

High Healthcare Spending in Developed Economies

Challenges: Lack of Awareness about the Therapeutic Drug Treatment

Increasing Number of Side Effects Post Immuno Oncology Therapy

Presented By

AMA Research & Media LLP

[neha24blog]

Immuno-oncology Clinical Trials Market is Predicted to Observe a Tremendous Growth, With a CAGR of 13.6% From 2021 To 2028: Grand View Research Inc.

Immuno-oncology Clinical Trials Market is Predicted to Observe a Tremendous Growth, With a CAGR of 13.6% From 2021 To 2028: Grand View Research Inc.

San Francisco, 12 July 2021: The Report Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Design (Interventional Trials, Observational Trials), By Indication, By Region, And Segment Forecasts, 2021 – 2028 The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028, according…

[databrigemarketresearchreports]

Immuno-Oncology Clinical Trials Market Outlook, Research, Trends and Forecasts to 2029

The market analysis of Immuno-Oncology Clinical Trials market research report provides an examination of various market segments that are supposed to witness the fastest development amid the estimated forecast frame. A comprehensive market research has been conducted in this report which puts a light on the challenges, market structures, opportunities, driving forces, scope, and competitive landscape for the business. The best tools have been adopted to generate this report which is SWOT analysis and Porter’s Five Forces analysis. This market report is truly a key to achieve the new horizon of success. Immuno-Oncology Clinical Trials is a professional and exhaustive report which focuses on primary and secondary drivers, market share, leading segments and geographical analysis. In Immuno-Oncology Clinical Trials market document, a market study and overview is carried out by taking into account market drivers, market restraints, opportunities and challenges for a particular business. Geographical scope of the products is also taken into consideration methodically for the major global areas such as Asia, North America, South America, and Africa. This helps delineate strategies for the product distribution in those areas. The market report estimates the size of the market with respect to the information on key retailer revenues, development of the industry by upstream and downstream, industry progress, key companies, key developments, along with market segments and application. The superior Immuno-Oncology Clinical Trials market report is presented with a full devotion and dedication to the clients that extend their reach to success. Ask for Sample Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-oncology-clinical-trials-market

Some of the market players studied in this report are:

Olympus Corporation, KLS Martin Group, B. Braun Melsungen AG, Medtronic, OmniGuide Holdings, Inc., biolitec AG, Intuitive Surgical, Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, Scanlan International, Getinge AB, and Johnson & Johnson Private Limited, among others.

 The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of phase, the     immuno-oncology clinical trials market is segmented into phase I, phase     II, phase III, and phase IV.

On the basis of design, the     immuno-oncology clinical trials market is segmented into interventional     trials, observational trials, and expanded access trials.

On the basis of indication, the     immuno-oncology clinical trials market is segmented into solid tumours,     and hematological cancer.

Topical Retinoid Speak to Analyst https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-immuno-oncology-clinical-trials-market The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials market.

Product Development/Innovation: Detailed insights on the upcoming technologies, RD activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Global Immuno-Oncology Clinical Trials market.

Why should buy this report?

·         Provides in depth research analysis of the overall Immuno-Oncology Clinical Trials market. which can help save time for start-up businesses related to the Immuno-Oncology Clinical Trials Market.

·         The Immuno-Oncology Clinical Trials markets latest news, forecast analysis as well as the key competitors of the market are easily available with all the necessary information.

·         The Immuno-Oncology Clinical Trials report comprises of graphs, pie charts and other representations that can help the reader understand the information at a glance.

·         Through the Immuno-Oncology Clinical Trials report the manufacturers can understand the consumer behaviour, business segments as well as sell products-based information provided.

Request for Customization https://www.databridgemarketresearch.com/customization/global-immuno-oncology-clinical-trials-market

Thank you for reading our report. For further inquiry, please get in touch with us. Our team will ensure the report is customized to meet your requirements.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com 

[rahulg1122]

Nasal Drug Delivery Technology Market to reach USD 64.20 billion by 2021

The global nasal drug delivery technology market is projected to reach USD 64.20 billion by 2021 from USD 44.00 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing patient preference for nasal drug delivery as a result of easy administration & better efficacy and growing adoption of self-administration practices are some of the major factors driving the growth of the nasal drug delivery technology market. Intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers. This can be majorly attributed to the non-invasive nature of this route of delivery and the fact that drug absorbability is higher through the nasal route. 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=192818058

Key Players of Market

Key players in the nasal drug delivery technology market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson& Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca Plc.(U.S.), Aptar Group (U.S.), and GlaxoSmithKline plc (U.K.) 

Major Market Developments

In 2016, Pfizer collaborated with Western Oncolytics to advance Western Oncolytics’ novel oncolytic vaccinia virus. This collaboration helped Pfizer to enhance its novel technology platform for cancer Vaccines and strengthened its immuno-oncology portfolio.

In 2016, GlaxoSmithKline collaborated with Vaccine Research Center at the NIH (US) to evaluate a new vaccine technology for Zika, known as SAM.

In 2017, Merck collaborated with Premier, Inc. (US) to develop a preventive care model that seeks to improve adolescent and adult vaccination rates.

Get a Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=192818058

Furthermore, growth among over-the-counter nasal drugs and increasing focus on alternative routes of drug delivery such as nasal drug delivery offer significant growth opportunities for player operating in the market. On the other hand, complications associated with the overuse of nasal sprays may restraint the growth of the nasal drug delivery technology market.

The nasal drug delivery technology market is segmented based on dosage form, therapeutic application, end user, system, container, and region. On the basis of system, the market is segmented into multi-dose systems, bi-dose systems, and unit-dose systems. In 2016, the multi-dose drug delivery systems segment is expected to account for the largest share of the nasal drug delivery technology market. This can primarily be attributed to the growing preference for multi-dose drug delivery as these systems provide quick and effective delivery of drugs into the bloodstream.

The nasal drug delivery technology market in Asia is expected to grow at the highest CAGR during the forecast period. Opportunities in the Asian market have attracted huge investments by major companies in the area of R&D activities. In addition, the region has low costs of labor and clinical trials, which has further served to draw market players to Asia.

[rohans18]

Immuno-Oncology Clinical Trials Market Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2029

Global Immuno-Oncology Clinical Trials Market, By Phase (Phase I, Phase I, Phase III, Phase IV), Design (Interventional Trials, Observational Trials, Expanded Access Trials), Indication (Solid Tumours, Hematological Cancer), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

The consistent Immuno-Oncology Clinical Trials Market market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Immuno-Oncology Clinical Trials Market market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Some of the major players operating in the immuno-oncology clinical trials market report are Olympus Corporation, KLS Martin Group, B. Braun Melsungen AG, Medtronic, OmniGuide Holdings, Inc., biolitec AG, Intuitive Surgical, Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, Scanlan International, Getinge AB, and Johnson & Johnson Private Limited, among others.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-clinical-trials-market

One of the principal objectives of a high-ranking Immuno-Oncology Clinical Trials Market industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Immuno-Oncology Clinical Trials Market market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Immuno-Oncology Clinical Trials Market market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials Market Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[cavixorg]

Using its unique expanded genetic code technology platform, Ambrx Biopharma Inc.(AMAM stock) , a clinical-stage biologics firm, discovers and creates tailored precision biologics. Its lead product candidate, ARX788, is an anti-HER2-drug conjugate (ADC) that is being studied in numerous clinical trials to treat of breast cancer, stomach junction cancer, as well as other solid tumors. These trials, which are currently in Phase 2 and Phase 3, are also being conducted for the treatment of gastric and breast cancers that have metastasized and are HER2-positive. The company is also working on two earlier-stage product candidates: ARX305, an anti-CD70 ADC in investigational new chemical studies for the treatment of kidney cell carcinoma and other cancers.  And ARX517, an anti-PSMA ADC in a Phase 1 clinical trial for the therapy of prostate cancer and other tumors. It is also creating additional multiple product candidates with an eye toward immuno-oncology applications, such as ARX102, an immuno-oncology IL-2 path agonist that targets and gamma receptors on cytotoxic T cells to activate the patient's own immune system, and ARX822, a fab-small macromolecular bispecific that is used in preclinical phase for cancers. Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health are all partners of Ambrx Biopharma Inc. The business was founded in 2003, and its main office is in La Jolla, California. Who Are The Major Owners Of AMAM Stock? 17 investment banks and fund managers owned AMAM stock in Ambrx Biopharma over the previous two years. Fosun International Ltd ($37.88M), Adage Capital Partners GP L.L.C. ($17.37M), BlackRock Inc. ($11.75M), FMR LLC ($10.22M), Octagon Capital Advisors LP ($8.82M), Suvretta Capital Management LLC ($6.15M), and Millennium Management LLC ($2.82M) were the institutional investors with the largest investments. AMAM stock is held by institutions 44.21% of the time. In the past 24 months, institutional investors have purchased 9,197,182 shares altogether. This volume of purchases entails about $158.86M in transactions. In the past 24 months, investment banks have sold 274,909 shares in total. This share sale volume equates to roughly $1.55M in business. Institutional shareholders Cormorant Asset Management LP ($0.15M), BlackRock Inc. ($48.46K), Tudor Investment Corp Et Al ($39.86K), Ghisallo Capital Management LLC ($25K), and Renaissance Technologies LLC ($11.60K) all sold shares of Ambrx Biopharma in the past 24 months. Short Sellers Of Ambrx Biopharma? November saw a decrease in short interest in Ambrx Biopharma. 3,800 shares totaled short interest as of November 15th, which is a decrease of 20.8% from the 4,800 share total as of October 31st. The days-to-cover ratio is currently 0.1 days based on an average daily trading volume of 30,600 shares. Short sales of the company's shares make up about 0.0% of the total. Any online trading account can be used to buy shares of AMAM stock. WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab are a few well-known online brokerages providing access to the American stock market.   Competitors Of AMAM The top rivals of Ambrx Biopharma include Elevation Oncology (ELEV), Cortexyme, Idera Pharmaceuticals (IDRA), Rubius Therapeutics (RUBY), Jasper Therapeutics (JSPR), Entera Bio (ENTX), AIM ImmunoTech (AIM), ERYTECH Pharma (ERYP), Genetic Technologies (GENE), Surrozen (SRZN), and (CRTX). All of these businesses fall under the "medical" category. Ambrx Biopharma is not as well-liked by analysts as other Medical companies. AMAM stock has a consensus rating of Moderate Buy, whereas the typical consensus rating for healthcare firms is Buy. Ambrx Biopharma is disliked by customers more than other Medical businesses. Ambrx Biopharma had an outperform vote from 52.38% of people, versus an average of 66.26% for medical firms. Entera Bio And Ambrx Biopha

rma? Compared to Ambrx Biopharma, Entera Bio has smaller revenue but larger earnings. Shares in Ambrx Biopharma are held by institutions 44.2% of the time. Comparatively, institutional investors own 17.1% of the shares in Entera Bio. Shares of Ambrx Biopharma are held by company insiders to a 5.1% stake. Comparatively, insiders own 5.2% of the shares in Entera Bio. Solid organizational ownership is a sign that endowments, hedge funds, and big money managers are betting on a company's long-term ability to outperform the market. Compared to Entera Bio's profit income of -1,796.49%, Ambrx Biopharma has a net margin of 0.00%. Entera Bio's return on equity was beaten by Ambrx Biopharma's equity return of 0.00%. When compared by users, Entera Bio earned 157 more votes for outperformance than Ambrx Biopharma. Similarly, while just 52.38% of people gave Ambrx Biopharma an outstanding vote, 66.14% of users awarded Entera Bio an outperform rating. With a beta of 1.34, AMAM stock price is 34% less volatile than that of the S&P 500. Compared to the S&P 500, Entera Bio's share price is 84% more unpredictable with a beta of 1.84. Ambrx Biopharma received 48 more media mentions than Entera Bio in the past week. Ambrx Biopharma received 49 mentions according to us, while Entera Bio received just one. Shares Of Ambrx Rise After Promoting Early Safety Preliminary safety and effectiveness findings from the Phase 2 ACE-Breast-03 study were released by Ambrx Biopharma Inc. (NASDAQ: AMAM), which encouraged early safety data from the breast cancer candidate. In patients with HER2-positive mBC who are resistant or refractory to T-DM1, the data showed a 51.7% overall response rate (ORR) and a 100% disease control rate (DCR) after therapy with ARX788. Patients received therapy for a median of 7.2 months, as treatment is still ongoing. In China, Amrbrx's partner NovoCodex Biopharmaceuticals is currently conducting two Phase 3 trials so one registration-enabled Phase 2 study with ARX788, with readouts expected in 2023. The last check Friday's premarket session saw AMAM shares up 180.6% to $1.15. How Simple Is It For Ambrx Biopharma To Raise Money? Many people may be thinking that Ambrx Biopharma has to raise more money in the future because its income is falling and its operating cash flow is rising. Companies have the option of raising capital through debt or equity. Publicly traded corporations benefit greatly from the ability to sell investors shares in order to raise capital and finance expansion. By comparing a company's cash burn to its market capitalization, we may determine how much investors would be affected if the business had to issue capital to pay for the cash burn for an additional year. Ambrx Biopharma seems to have a market value of $20 million and spent $7 million last year, or 350% of its market value. We believe there is a substantial risk of financial hardship given how big that expenditure is in comparison to the company's market value, and we would be extremely cautious about keeping the AMAM stock. What Are The Average Rating And Price Objective For Ambrx Biopharma? Based on the current 1 controlled transaction and 1 buy rating for AMAM, the consensus opinion for AMAM stock is Moderate Buy, according to the 2 analysts who have issued ratings in the past year. Ambrx Biopharma's average 12-month price objective is $4.00, with a premium price target of $4.00 and a low cost target of $4.00. According to two Wall Street experts who have predicted the price of AMAM for the next year, the average price target is $11.00, with the maximum prediction for the company being $16.00 and the lowest prediction being $6.00. By April 2023, according to the majority of Wall Street analysts, the share price of Ambrx Biopharma might be $11.00. Is AMAM A Successful Business? The cash burn for AMAM is $70163000. It has at least a year's worth of coverage in the form of cash and short-term investments. AMAM has cash and short-term investments of

$111.72 million. This is sufficient to fund its $70.16M yearly cash burn. AMAM has a small 0.28 debt to equity ratio. On the balance sheet of AMAM, short-term assets outnumber long-term liabilities. On the balance sheet of AMAM, short-term assets exceed short-term liabilities. Cons: Over the past year, AMAM's profit margin has decreased from 325.6% to 1.729.9%. According to our examination of Ambrx Biopharma's cash position, its cash runway was comforting, but the ratio of its cash burn to market value has us a little concerned. We have very little faith in the company's capacity to control its cash burn after taking all the data stated in this article into account, and we predict it will need additional money. The Basics Of Ambrx Biopharma The value of AMAM stock is 43, which is higher than the average for the Biotechnology sector. Currently, 3 out of 7 due diligence tasks are being passed by AMAM. AMAM's Financials rating is 0, which is the same as the industry average for the Biotechnology sector. AMAM stock is presently failing 0 of 7 checks for due diligence. The AMAM stock forecast score is 0, which is the same as the sector average for biotechnology. AMAM stock is presently failing 0 of 9 checks for due diligence. The Performance score for AMAM stock is 71, which is higher than the industry average for biotechnology. Five out of ten due diligence checks are passing for AMAM. We disregard this dimension because Ambrx Biopharma has little or no historical dividend history. Recommendations Most Recent From AMAM Analysts On May 24, 2022, a Goldman Sachs analyst decreases their price objective for AMAM stock from $6 to $4 while maintaining a hold rating. On April 7, 2022, Joel Beatty, a high 17% analyst from Baird, commences covering on AMAM with a buy recommendation and publishes their $16.00 price target. On February 28, 2022, Corinne Jenkins of Goldman Sachs, a top 48% analyst, announces the beginning of covering on AMAM with such a hold recommendation and a $6.00 price target. In 2022, Should I Buy Or Sell Ambrx Biopharma Stock? In the past year, Ambrx Biopharma has received "buy," "hold," and "sell" evaluations from 2 Wall Street research analysts. For the stock, there is presently 1 hold rating and 1 buy rating. Wall Street research experts generally agree that investors should "buy" AMAM stock. On Friday, June 18th 2021, (AMAM) raised $126 million through an initial public offering. At a price of $17.00–$19.00 per share, the corporation issued 7,000,000 shares. The underwriters for the initial public offering were Goldman Sachs, BofA Securities, and Cowen. The time it would take for a corporation to exhaust its cash on hand at its current cash burn rate is known as its cash runway. Ambrx Biopharma had 111 million dollars in cash and no debt as of June 2022. Looking back at the previous year, the business spent $70 million. So, starting in June 2022, AMAM stock forecast had a financial runway of about 19 months. This is not too bad, and unless cash burn substantially decreases, it is safe to assume the financial runway is coming to an end. Ambrx Biopharma Stock Forecast 2022 While it is not anticipated that AMAM stock forecast annual earnings rate of growth of N/A will surpass the statistically important earnings growth rate of 9.29% for the US biotechnology industry, neither is it anticipated to surpass the average AMAM stock forecast earnings rate of growth of 70.08% for the US market. The revenue for AMAM stock forecast in 2022 is -$90,558,000. One Wall Street analyst predicted that AMAM stock forecast earnings would be -$75,691,975 on average in 2022, with the highest AMAM earnings prediction being -$75,691,975 and the top AMAM stock forecast being -$75,691,975. The current Earnings Per Share (EPS) for Ambrx Biopharma is $6.72. Analysts expect AMAM stock forecast EPS to be -$0.28 on average for 2022, with the lowest and highest estimates both coming in at -$0.28. Ambrx Biopharma Stock Forecast

2023 AMAM stock forecast is anticipated to make -$67,582,121 in 2023, with the smallest earnings estimate being -$67,582,121 and the actual figure being -$67,582,121. By April 7, 2023, analysts on Wall Street believe the share price of Ambrx Biopharma might reach $11.00. From the present share price of $4.54 for AMAM, the average AMAM stock forecast predicts a possible increase of 142.29%. AMAM stock forecast EPS is anticipated to be negative $0.25 in 2023.